Medicare AdvantagePrior AuthMedium impact
Anzupgo® (delgocitinib) (New)
Humana·Dermatology, Family Medicine, Internal Medicine·Medicare Advantage
Effective date
Dec 17, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has added Anzupgo (delgocitinib) 2% topical cream as a new prior authorization requirement for chronic hand eczema treatment. Approval requires documentation of moderate to severe chronic hand eczema with previous failure, intolerance, or contraindication to at least two topical corticosteroids of moderate or higher potency.
Action Required
By December 17, 2025: Billing and clinical staff must implement prior authorization requirements for Anzupgo (delgocitinib) prescriptions for Humana Medicare Advantage patients. Providers must document: 1) moderate to severe chronic hand eczema diagnosis, 2) previous treatment failure/intolerance/contraindication to at least two topical corticosteroids (triamcinolone, mometasone, betamethasone, or clobetasol), and 3) topical application limited to hands and wrists. Visit www.humana.com/PAL for medical coding information. Claims without prior authorization will be denied.